SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Authors
Keywords
Diabetes mellitus, Diabetic kidney disease, Heart failure, Non-alcoholic fatty liver disease, Non-diabetic chronic kidney disease, Review
Journal
DIABETOLOGIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-21
DOI
10.1007/s00125-018-4678-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE
- (2016) Søren L. Kristensen et al. Circulation-Heart Failure
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Nephron Protection in Diabetic Kidney Disease
- (2016) Hans-Joachim Anders et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes
- (2015) Adam Ogna et al. EUROPEAN JOURNAL OF NUTRITION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension
- (2012) P. Palatini NEPHROLOGY DIALYSIS TRANSPLANTATION
- Paget's Disease of the Mandible
- (2008) Mayank B. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now